全文获取类型
收费全文 | 548篇 |
免费 | 54篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 4篇 |
妇产科学 | 3篇 |
基础医学 | 61篇 |
口腔科学 | 3篇 |
临床医学 | 44篇 |
内科学 | 305篇 |
神经病学 | 1篇 |
特种医学 | 4篇 |
外科学 | 12篇 |
综合类 | 2篇 |
预防医学 | 28篇 |
眼科学 | 4篇 |
药学 | 7篇 |
肿瘤学 | 107篇 |
出版年
2023年 | 4篇 |
2022年 | 2篇 |
2021年 | 5篇 |
2020年 | 6篇 |
2019年 | 6篇 |
2018年 | 13篇 |
2017年 | 8篇 |
2016年 | 12篇 |
2015年 | 4篇 |
2014年 | 8篇 |
2013年 | 18篇 |
2012年 | 27篇 |
2011年 | 21篇 |
2010年 | 7篇 |
2009年 | 6篇 |
2008年 | 14篇 |
2007年 | 29篇 |
2006年 | 27篇 |
2005年 | 21篇 |
2004年 | 42篇 |
2003年 | 25篇 |
2002年 | 31篇 |
2001年 | 30篇 |
2000年 | 33篇 |
1999年 | 25篇 |
1998年 | 6篇 |
1997年 | 11篇 |
1996年 | 7篇 |
1995年 | 3篇 |
1994年 | 10篇 |
1993年 | 3篇 |
1992年 | 15篇 |
1991年 | 12篇 |
1990年 | 17篇 |
1989年 | 15篇 |
1988年 | 10篇 |
1987年 | 12篇 |
1986年 | 7篇 |
1985年 | 11篇 |
1984年 | 11篇 |
1983年 | 5篇 |
1982年 | 8篇 |
1981年 | 7篇 |
1976年 | 1篇 |
1975年 | 2篇 |
1974年 | 1篇 |
1968年 | 1篇 |
1940年 | 2篇 |
1928年 | 1篇 |
排序方式: 共有602条查询结果,搜索用时 31 毫秒
1.
Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma 总被引:1,自引:0,他引:1
Meletios A. Dimopoulos Kay B. Delasalle Richard Champlin Raymond Alexanian 《British journal of haematology》1993,83(2):240-244
Few effective regimens are available for patients with advanced multiple myeloma resistant to or relapsing after both alkylating agents and VAD. We treated 52 patients with advanced and refractory multiple myeloma with the combination of cyclophosphamide (3.0 g/m2 ) and etoposide (900 mg/m2 ) followed by GM-CSF at a daily dose of 0.125 mg/m2 until recovery of granulocytes. 42% of patients responded with a median time of 19 d for recovery of granulocytes to 0.5 x 109 /1 and a 4% mortality rate. Eight responding patients received a second myeloablative treatment supported by either autologous bone marrow (six patients) or blood stem cells (two patients). The median survival time for all patients was 11 months and the median remission time for responding patients was 8 months. The combination of cyclophosphamide and etoposide provided an effective rescue treatment for many patients with advanced multiple myeloma resistant to conventional therapies. This programme also allowed early marrow or blood stem cell collection in support of subsequent myeloablative therapy for selected patients. 相似文献
2.
L Champlin 《Geriatrics》1991,46(8):67-70
New national campaign nurtures complementary programs to address a wide range of elderly care issues. 相似文献
3.
4.
W W Orrison Jr A M Champlin O L Kesterson M F Hartshorne J N King 《AJNR. American journal of neuroradiology》1994,15(5):913
Three cases of MR with gadopentetate dimeglumine in patients diagnosed with cerebral death are presented. Observation of an MR "hot nose sign" and an "intravascular enhancement sign" provided additional imaging support in the clinical diagnosis of brain death. The MR findings in brain death include: 1) transtentorial and foramen magnum herniation, 2) absent intracranial vascular flow void, 3) poor gray matter/white matter differentiation, 4) no intracranial contrast enhancement, 5) carotid artery enhancement (intravascular enhancement sign), and 6) prominent nasal and scalp enhancement (MR hot nose sign). Additional modalities for confirming brain death are discussed. 相似文献
5.
Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement 下载免费PDF全文
Talha Badar Amanda Megan Cornelison Nina D. Shah Qaiser Bashir Simrit Parmar Krina Patel Chitra Hosing Uday Popat Donna M. Weber Sheeba K. Thomas Jatin J. Shah Robert Z. Orlowski Richard E. Champlin Muzaffar H. Qazilbash 《European journal of haematology》2016,97(4):342-347
Cardiac involvement in systemic light chain amyloidosis (AL) is generally associated with a worse outcome, especially if other organs are also involved. We sought to determine whether concurrent cardiac and renal involvement were associated with a worse outcome than either organ alone. We identified 129 patients with AL, who received high‐dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto‐HCT) at our institution between 1997 and 2014. Ninety‐nine patients had either renal (group 1: n = 62, 62%), cardiac (group 2: n = 20, 20%), or both cardiac and renal (group 3: n = 17, 17%) involvement. The overall hematological response rate (CR+VGPR+PR) post‐auto‐HCT in groups 1, 2, and 3 was 69%, 74% and 82%, respectively (P = 0.62). Overall, organ response in groups 1, 2, and 3 was 39%, 42%, and 70%, respectively. The median PFS from auto‐HCT in groups 1, 2, and 3 was not reached (NR), 13.3 and 21 months, respectively (P = 0.02). The median OS in groups 1, 2, and 3 was 120, 46, and 60 months, respectively (P = 0.1). In conclusion, median PFS and OS in patients with concurrent cardiac and renal AL were comparable to patients with cardiac AL only, but worse than patients with renal AL. 相似文献
6.
Ueno NT Rizzo JD Demirer T Cheng YC Hegenbart U Zhang MJ Bregni M Carella A Blaise D Bashey A Bitran JD Bolwell BJ Elfenbein GJ Fields KK Freytes CO Gale RP Lazarus HM Champlin RE Stiff PJ Niederwieser D 《Bone marrow transplantation》2008,41(6):537-545
We reviewed 66 women with poor-risk metastatic breast cancer from 15 centers to describe the efficacy of allogeneic hematopoietic cell transplantation (HCT). Median follow-up for survivors was 40 months (range, 3-64). A total of 39 patients (59%) received myeloablative and 27 (41%) reduced-intensity conditioning (RIC) regimens. More patients in the RIC group had poor pretransplant performance status (63 vs 26%, P=0.002). RIC group developed less chronic GVHD (8 vs 36% at 1 year, P=0.003). Treatment-related mortality rates were lower with RIC (7 vs 29% at 100 days, P=0.03). A total of 9 of 33 patients (27%) who underwent immune manipulation for persistent or progressive disease had disease control, suggesting a graft-vs-tumor (GVT) effect. Progression-free survival (PFS) at 1 year was 23% with myeloablative conditioning and 8% with RIC (P=0.09). Women who developed acute GVHD after an RIC regimen had lower risks of relapse or progression than those who did not (relative risk, 3.05: P=0.03), consistent with a GVT effect, but this did not affect PFS. These findings support the need for preclinical and clinical studies that facilitate targeted adoptive immunotherapy for breast cancer to explore the benefit of a GVT effect in breast cancer. 相似文献
7.
Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction. 总被引:4,自引:1,他引:4
8.
Recently, adult stem cells originating from bone marrow or peripheral blood have been suggested to contribute to repair and genesis of cells specific for liver, cardiac and skeletal muscle, gut, and brain tissue. The mechanism involved has been termed transdifferentiation, although other explanations including cell fusion have been postulated. Using adult stem cells to generate or repair solid organ tissue obviates the immunologic, ethical, and teratogenic issues that accompany embryonic stem cells. 相似文献
9.
10.
Richard E. Champlin Stephen A. Feig Robert S. Sparkes Robert Peter Gale 《British journal of haematology》1984,56(3):455-463
S ummary . Treatment of aplastic anaemia by bone marrow transplantation from a syngeneic (identical twin) donor has provided insights into the pathophysiology of the disease.
We report from patients with severe anaemia who were treated by syngeneic bone marrow transplantation. None of the patients had sustained recovery of peripheral blood counts. All four received second transplants from the same twin donor after immunosuppressive conditioning treatment. Each had prompt recovery of haematopoiesis. A review of the literature indicates that failure of syngeneic bone marrow transplantation in patients with aplastic anaemia is not uncommon. These data indicate that aplastic anaemia may be caused by a mechanism other than an absence or intrinsic abnormality of haematopoietic stem cells in many patients. 相似文献
We report from patients with severe anaemia who were treated by syngeneic bone marrow transplantation. None of the patients had sustained recovery of peripheral blood counts. All four received second transplants from the same twin donor after immunosuppressive conditioning treatment. Each had prompt recovery of haematopoiesis. A review of the literature indicates that failure of syngeneic bone marrow transplantation in patients with aplastic anaemia is not uncommon. These data indicate that aplastic anaemia may be caused by a mechanism other than an absence or intrinsic abnormality of haematopoietic stem cells in many patients. 相似文献